Original source (on modern site) | Article images: [1]
OverT Bio, a NYC-based data-driven company working to enable the curative potential of cell therapies in solid tumors, raised $16M in Seed funding. The round was led by ARTIS Ventures and Wing VC, with participation from Fusion Fund, OMX Ventures, Alexandria Venture Investments, Gaingels, Civilization Ventures, Hawktail, and Cancer Research Institute. The company intends to use the funds to expand discovery platforms focused on addressing the primary barriers for cell therapy, leading to durable and curative treatments for advanced solid tumors. Founded in 2022 by Dr. Mat Legut and Dr. Neville Sanjana, OverT Bio has developed parallel genetic screening, single-cell multiomic, and synthetic biology platforms that combine cell engineering technologies with big data approaches to address major unmet medical needs in solid tumors. Its core platform searches every gene in the genome to identify the best genetic modifications to endow immune cells with novel properties. The company has also built a similarly high-throughput approach to discover new receptors and targets that are both safe and efficacious. OverT uses patients' immune response to cancer to find new receptors and targets that can be applied across the human population. The team searches the entire human genome to find new ways to make cell therapies more durable and capable of destroying cancers. FinSMEs 06/05/2024
![[1]](image.php?loc=LB&i=https://www.finsmes.com/wp-content/uploads/2017/04/cancer.jpg){kind=link}